Loading…
avatar for Rebecca Blanchard, Ph.D.

Rebecca Blanchard, Ph.D.

CRISPR Therapeutics, Cambridge, MA
Vice President, Translational Pharmacology
Dr. Blanchard’s career in academia and industry has spanned basic, translational, and clinical research and development across multiple therapeutic areas.  She is currently Vice President of Translational Pharmacology at CRISPR Therapeutics where she is responsible for Safety Toxicology, Assay Development and Biomarker Research activities.  Rebecca is also the Project Lead on CRISPR Therapeutics’ first CAR T program, CTX110 (anti CD19 CAR T cell).  Rebecca’s education includes a B.S. in Pharmacy from Albany College of Pharmacy and a Ph.D. in Pharmaceutical Chemistry from the University of Utah.  Rebecca completed postdoctoral studies at the Mayo Clinic with a focus on human pharmacogenetics.  From 1998 through 2004 Rebecca was an Assistant Professor at Fox Chase Cancer Center in Philadelphia where her research focused on pharmacogenomics as related to anticancer therapies.  Prior to joining CRISPR Therapeutics in 2018, Rebecca spent 13 years at Merck, Inc. where she held positions of increasing responsibility across several departments in both research and clinical development. Rebecca was most recently head of Clinical Pharmacogenomics within the Dept of Genetics and Pharmacogenomics where she was responsible for the scientific strategy and execution of Merck’s Clinical Pharmacogenomics efforts.  While also at Merck, she held prior positions as Senior Project Leader in Oncology and Clinical Director in Clinical Pharmacology and led several Drug Development teams across early and late stage development.  Throughout her career, Rebecca has demonstrated a strong external scientific presence as evidenced by her roles on the ASCPT Board of Directors; ICH E18 Working Group; National Academy of Sciences, Engineering and Medicine Genomics Roundtable, Industry Pharmacogenomics Working Group and ACPHS Scientific Advisory Board.